This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

BiomX Future Growth

Future criteria checks 0/6

BiomX's earnings are forecast to decline at 15.7% per annum while its annual revenue is expected to grow at 95.3% per year. EPS is expected to grow by 4% per annum.

Key information

-15.7%

Earnings growth rate

4.0%

EPS growth rate

Biotechs earnings growth	28.4%
Revenue growth rate	95.3%
Future return on equity	n/a
Analyst coverage	Low
Last updated	19 Sep 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

NYSEAM:PHGE.U - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-45	N/A	N/A	2
12/31/2025	N/A	-39	N/A	34	2
12/31/2024	N/A	-30	N/A	32	2
6/30/2024	N/A	-26	-35	-35	N/A
3/31/2024	N/A	-34	-28	-28	N/A
12/31/2023	N/A	-26	-21	-21	N/A
9/30/2023	N/A	-27	-22	-22	N/A
6/30/2023	N/A	-25	-22	-22	N/A
3/31/2023	N/A	-27	-27	-27	N/A
12/31/2022	N/A	-28	-29	-29	N/A
9/30/2022	N/A	-33	-31	-31	N/A
6/30/2022	N/A	-36	-33	-31	N/A
3/31/2022	N/A	-36	-31	-29	N/A
12/31/2021	N/A	-36	-31	-28	N/A
9/30/2021	N/A	-35	-30	-26	N/A
6/30/2021	N/A	-34	-29	-26	N/A
3/31/2021	N/A	-33	-26	-24	N/A
12/31/2020	N/A	-30	-25	-24	N/A
9/30/2020	N/A	-27	-25	-24	N/A
6/30/2020	N/A	-23	-24	-23	N/A
3/31/2020	N/A	-22	-23	-21	N/A
12/31/2019	N/A	-21	-19	-18	N/A
9/30/2019	N/A	-22	-15	-14	N/A
6/30/2019	N/A	-19	-13	-12	N/A
3/31/2019	N/A	-17	-12	-12	N/A
12/31/2018	N/A	-15	-11	-11	N/A
12/31/2017	N/A	-7	N/A	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHGE.U is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PHGE.U is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PHGE.U is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PHGE.U is forecast to have no revenue next year.

High Growth Revenue: PHGE.U is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PHGE.U's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

BiomX Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

BiomX Inc. to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

Biomx Inc. to Present Positive Phase 1B/2A Clinical Trial Data for Bx004 At the European Respiratory Society (Ers) Congress 2024

BiomX Announces NYSE American Acceptance of Plan to Regain Listing Compliance

BiomX Inc., Annual General Meeting, Jul 09, 2024

BiomX Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

BiomX Inc. to Report Q1, 2024 Results on May 21, 2024

Biomx Inc. Appoints Susan Blum to Its Board of Directors and Member and Chair of the Audit Committee of the Board

BiomX Inc. announced delayed annual 10-K filing

BiomX Inc. announced that it has received $50.013969 million in funding from Deerfield Management Company, LLC, AMR Action Fund GP, LLC, Cystic Fibrosis Foundation, Nantahala Capital Management, LLC, OrbiMed Advisors LLC

BiomX Inc. announced that it expects to receive $50.013969 million in funding

BiomX Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Biomx Announces Positive Topline Results from Part 2 of the Phase 1B/2A Trial Evaluating Bx004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Biomx to Present Data from Ongoing Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis

BiomX Inc. Announces the Appointment of Edward L. Williams to its Board of Directors

BiomX Inc. Announces Completion of Patient Dosing in Part 2 of Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Biomx Inc. to Present Part 1 Data from Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session At The46th European Cystic Fibrosis Conference

Biomx Inc. Appoints Jason M. Marks and Michael E. Dambach to the Board of Directors

BiomX Inc. Announces Board Resignations

BiomX Inc. Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease

BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange

BiomX Inc. Announces Dosing of the First Two Patients in Phase 1B/2A Study of Bx004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

BiomX Inc., Annual General Meeting, Aug 24, 2022

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies